Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVA NASDAQ:NVAX NASDAQ:XOMA NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.64B0.35870,504 shs845,393 shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shsXOMAXOMA Royalty$42.09-0.7%$39.14$22.29▼$42.81$531.74M0.88100,046 shs41,952 shsXOMAOXOMA$25.42+0.2%$25.45$24.86▼$26.40N/AN/A3,975 shs4,643 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva+2.12%+1.23%-2.16%+0.59%+6.13%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%XOMAXOMA Royalty+1.68%+1.68%+1.78%+63.20%+69.60%XOMAOXOMA-0.14%-0.08%+0.26%-0.37%+0.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$22.52+1.6%$22.88$16.52▼$25.15$1.64B0.35870,504 shs845,393 shsNVAXNovavax$9.49-6.9%$8.92$6.13▼$11.97$1.68B2.455.74 million shs4.57 million shsXOMAXOMA Royalty$42.09-0.7%$39.14$22.29▼$42.81$531.74M0.88100,046 shs41,952 shsXOMAOXOMA$25.42+0.2%$25.45$24.86▼$26.40N/AN/A3,975 shs4,643 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva+2.12%+1.23%-2.16%+0.59%+6.13%NVAXNovavax-0.10%-1.26%+25.93%+2.10%+42.52%XOMAXOMA Royalty+1.68%+1.68%+1.78%+63.20%+69.60%XOMAOXOMA-0.14%-0.08%+0.26%-0.37%+0.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 2.57Moderate Buy$36.2060.75% UpsideNVAXNovavax 2.10Hold$12.1327.77% UpsideXOMAXOMA Royalty 2.14Hold$53.7527.70% UpsideXOMAOXOMA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XOMA, XOMAO, NVAX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/29/2026XOMAXOMA Royalty Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/22/2026XOMAXOMA Royalty BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2026XOMAXOMA Royalty Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/30/2026XOMAXOMA Royalty HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$39.004/27/2026XOMAXOMA Royalty Lucid Cap MktsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2026NVAXNovavax B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$411.33M4.04$5.12 per share4.40$15.71 per share1.43NVAXNovavax$1.12B1.39$3.27 per share2.90($0.79) per share-12.01XOMAXOMA Royalty$52.15M10.12$0.57 per share74.37$6.77 per share6.22XOMAOXOMA$7.65MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$271.17M$6.013.759.27N/A119.89%33.33%22.67%8/5/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)XOMAXOMA Royalty$31.71M$1.5726.81N/AN/A53.46%12.56%4.11%7/30/2026 (Estimated)XOMAOXOMAN/AN/AN/AN/AN/AN/AN/AN/A7/30/2026 (Estimated)Latest XOMA, XOMAO, NVAX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026XOMAXOMA Royalty$0.19$0.17-$0.02$0.17$13.91 million$12.32 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million3/18/2026Q4 2025XOMAXOMA Royalty-$0.04$0.12+$0.16$0.26$11.13 million$13.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/AXOMAOXOMA$2.098.22%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.1921.1320.07NVAXNovavaxN/A2.482.45XOMAXOMA Royalty0.963.593.59XOMAOXOMAN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%NVAXNovavax53.04%XOMAXOMA Royalty95.92%XOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipINVAInnoviva2.01%NVAXNovavax1.60%XOMAXOMA Royalty8.90%XOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10073.81 million72.33 millionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableXOMAXOMA Royalty1012.54 million11.43 millionOptionableXOMAOXOMA10N/AN/ANot OptionableXOMA, XOMAO, NVAX, and INVA HeadlinesRecent News About These CompaniesShort Interest in XOMA Co. (NASDAQ:XOMAO) Drops By 52.8%May 31, 2026 | americanbankingnews.comXOMA Stock (NASDAQ:XOMAO), Earnings Estimates, EPS, and RevenueMay 27, 2026 | benzinga.comLigand snaps up fellow biotech royalty aggregator Xoma for $739MApril 27, 2026 | fiercepharma.comFLigand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 millionApril 27, 2026 | msn.comLigand Pharmaceuticals buying Xoma Royalty for $739 millionApril 27, 2026 | finance.yahoo.comLigand Pharmaceuticals: Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | finanznachrichten.deLigand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 millionApril 27, 2026 | msn.comXOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO)April 12, 2026 | nasdaq.comXOMA Royalty Corp. Dep. Pfd. (Rep. 8.375% Cum. Pfd. Series B)April 12, 2026 | barrons.comXoma Royalty Stock Gains on Unexpected 4Q ProfitMarch 18, 2026 | marketwatch.comXOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.February 10, 2026 | finanznachrichten.deINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty ...January 6, 2026 | caledonianrecord.comCAnalysts Have Conflicting Sentiments on These Healthcare Companies: InflaRx (IFRX) and Xoma (XOMA)January 1, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Xoma (XOMA) and InflaRx (IFRX)January 1, 2026 | theglobeandmail.comHC Wainwright remains bullish on Xoma following creative Takeda dealDecember 31, 2025 | msn.comXOMA and Takeda execute royalty sharing transactionDecember 31, 2025 | thepharmaletter.comTXOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three yearsDecember 21, 2025 | finance.yahoo.comXOMA Royalty Corporation - Preferred Stock (XOMAP) price target increased by 11.43% to 68.83December 21, 2025 | msn.comXOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co.December 17, 2025 | finanznachrichten.deGeneration Bio is latest Mass. biotech to be acquired by XomaDecember 16, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, XOMAO, NVAX, and INVA Company DescriptionsInnoviva NASDAQ:INVA$22.52 +0.36 (+1.62%) Closing price 04:00 PM EasternExtended Trading$22.52 +0.00 (+0.02%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$9.49 -0.70 (-6.87%) Closing price 04:00 PM EasternExtended Trading$9.39 -0.10 (-1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.XOMA Royalty NASDAQ:XOMA$42.09 -0.31 (-0.73%) Closing price 04:00 PM EasternExtended Trading$42.12 +0.03 (+0.08%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.XOMA NASDAQ:XOMAO$25.42 +0.06 (+0.22%) Closing price 03:54 PM EasternExtended Trading$25.42 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
